AlphAIalphai — Financial news for AI agents
investing.comAUG 72 min read$BLSM

BlossomHill Therapeutics prices $150M IPO at $16 per share

BlossomHill Therapeutics priced its IPO at $16.00 per share, selling 9,375,000 shares to raise about $150.0 million in gross proceeds, according to the company’s Aug. 6, 2026 press release. The offering was upsized and includes a 30-day option for 1,406,250 more shares. Shares are set to trade on Nasdaq as BLSM on Aug. 7, 2026.

Original reporting
investing.com
Published Aug 7, 2026, 12:19 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 12:43 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefIPO
Primary signal
$BLSM
Neutral
medium confidence
Mentioned
$BLSM
Relevance
8/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$BLSMNeutralMed
01

Why it matters

The key tradable event is the IPO pricing and scheduled Nasdaq start, which affects near-term order flow, volatility, and risk for any IPO-focused strategy.

02

Market read

This is a primary capital-markets disclosure: IPO size, price, and debut timing for BLSM.

03

What to watch

No details are provided on lockups, investor allocation, or valuation vs peers, which are key drivers of first-day trading and post-IPO drift.

Relevance 8/10Novelty 8/10Timing: IPO priced Aug. 6, expected to begin trading Aug. 7 on Nasdaq.

Background

BlossomHill Therapeutics is a clinical-stage biopharmaceutical company developing small molecule cancer treatments, with lead programs BH-30643 (EGFR inhibitor) and BH-30236 (CLK inhibitor).

Company-level read

Ticker impact

$BLSMNeutralMedium confidence
Context

BlossomHill Therapeutics priced its IPO at $16 and set a Nasdaq debut under ticker BLSM, with $150M gross proceeds and an over-allotment option.

Expected impact

Likely elevated first-day volatility around the Aug. 7 Nasdaq start, with direction dependent on demand versus the $16 offer price.

Evidence & confidence

The article discloses offer size, price, and listing timing, which are actionable for positioning around the debut, but it provides no new clinical or financial performance data.

Market effects

Sector

Adds a new clinical-stage small-molecule oncology IPO to the biotech pipeline, which can marginally affect sentiment toward early-stage financings.

Regional

Primarily US-focused listing and capital raise; limited spillover beyond Nasdaq biotech flows.

Global

Low global relevance given the article is US IPO mechanics rather than international regulatory or trial outcomes.

Counterpoint

What could challenge this read

IPO pricing at $16 does not guarantee post-listing performance; demand could be weaker than implied, leading to early selling pressure.

Key entities

  • company
    BlossomHill Therapeutics, Inc.

    Clinical-stage biopharmaceutical company that priced its IPO at $16 per share and plans Nasdaq trading under BLSM.

  • venue
    Nasdaq Global Select Market

    Planned listing venue for the IPO shares beginning Aug. 7, 2026.

  • financial_advisors
    J.P. Morgan, Leerink Partners, Guggenheim Securities

    Lead book-running managers for the IPO.

Read at source← All news

Related articles

AUG 28
$NEOHighAI 8/10

Biotech Stocks At 52-Week Highs - NEO, BLSM, RVMD, ORMP, CADL

NeoGenomics (NEO), BlossomHill Therapeutics (BLSM), Revolution Medicines (RVMD), Oramed Pharmaceuticals (ORMP), and Candel Therapeutics (CADL) reached 52-week highs on August 27, 2026. NEO reported Q2 revenue growth of 11% and a profit turnaround. BLSM began trading on Nasdaq and received FDA Fast Track designation. RVMD's lead drug, Rasonque, was FDA-approved. ORMP's net income increased significantly. CADL reported a higher net loss but plans a BLA filing for its lead drug.

rttnews.com4 min
AUG 18
$BLSMMedAI 8/10

BlossomHill Wins FDA Fast Track For BH-30643 In EGFR-Mutant NSCLC;Stock Up

BlossomHill Therapeutics (BLSM) said the FDA granted Fast Track designation to its investigational OMNI-EGFR inhibitor BH-30643 for adults with advanced or metastatic EGFR C797S-positive NSCLC after prior third-generation EGFR TKI therapy. The company noted Fast Track may enable more frequent FDA interactions and rolling NDA review. BH-30643 is in a Phase 1/2 SOLARA trial. BLSM shares rose to $16.38.

rttnews.com4 min
AUG 18
$BLSMMedAI 8/10

BlossomHill Therapeutics, Inc.: BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC

BlossomHill Therapeutics (Nasdaq: BLSM) said the FDA granted Fast Track designation to BH-30643 for advanced or metastatic EGFR C797S-positive NSCLC after prior third-generation EGFR TKI treatment. BH-30643 is in the SOLARA Phase 1/2 first-in-human trial (NCT06706076) across 40+ sites in 10 countries.

finanznachrichten.de4 min
AUG 7
MedAI 8/10

Latham & Watkins Advises on BlossomHill Therapeutics’ Upsized US$150 Million IPO

BlossomHill Therapeutics priced an upsized US$150 million IPO, selling 9,375,000 shares at US$16.00 each, with gross proceeds expected to be US$150.0 million before fees. The underwriters received a 30-day option to buy up to 1,406,250 additional shares. Latham & Watkins advised the underwriters, with FDA and other specialty support.

lw.com2 min
AUG 7
$BLSMMed

BlossomHill Therapeutics shares fall in debut after IPO

BlossomHill Therapeutics Inc. (NASDAQ:BLSM) shares fell 1.6% in their trading debut after the oncology-focused biotech raised $150 million in an upsized U.S. IPO. The stock opened at $15.75 versus a $16 IPO price, with 9.375 million shares priced at $16. Gross proceeds were expected at $150.0 million, and the firm valued around $482.6 million.

investing.com3 min